Goldman Sachs Maintains Buy on Maravai LifeSciences, Lowers Price Target to $35
Goldman Sachs maintains Maravai LifeSciences (NASDAQ:MRVI) with a Buy and lowers the price target from $44 to $35.
Maravai LifeSciences Q1 Adj. EPS $0.54 Beats $0.44 Estimate, Sales $244.30M Beat $232.30M Estimate
Maravai LifeSciences (NASDAQ:MRVI) reported quarterly earnings of $0.54 per share which beat the analyst consensus estimate of $0.44 by 22.73 percent. This is a 107.69 percent increase over earnings of $0.26 per share
Earnings Scheduled For May 5, 2022
Companies Reporting Before The Bell
• Mirum Pharmaceuticals (NASDAQ:MIRM) is expected to report quarterly loss at $1.34 per share on revenue of $8.46 million.
10 Health Care Stocks Whale Activity In Today’s Session
This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Maravai Lifesciences Holdings Inc Rejects $42/Share All-cash Offer From Sartorius AG
- Reuters Citing Sources
UPDATE: Maravai LifeSciences Q4 EPS $0.45 Beats $0.38 Estimate, Sales $228.44M Beat $208.09M Estimate
Maravai LifeSciences (NASDAQ:MRVI) reported quarterly earnings of $0.45 per share which beat the analyst consensus estimate of $0.38 by 18.42 percent. This is a 246.15 percent increase over earnings of $0.13 per share
The Daily Biotech Pulse: Kodiak Sinks On Adverse Study Outcome, Marinus Flags Delay In Clinical Trial, Mainz Biomed Gains On Positive Regulatory Development
Here's a roundup of top developments in the biotech space over the last 24 hours.
Stocks In Focus
Kodiak's Wet AMD Treatment KSI-301 Did Not Meet Primary Endpoint In Phase 2b/3 Study
Earnings Scheduled For February 23, 2022
Companies Reporting Before The Bell
• Sapiens Intl Corp (NASDAQ:SPNS) is likely to report earnings for its fourth quarter.
The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow
Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries.
Maravai LifeSciences Acquires MyChem For $240M In Cash At Closing With Potential For Additional Cash Consideration Based On Certain Conditions
MyChem's nucleotide synthesis methods are highly complementary to Maravai's TriLink mRNA technologies
Increases capabilities serving the high-growth cell and gene therapy market
SAN DIEGO, Jan. 28, 2022 (GLOBE